CD19


Also found in: Wikipedia.

CD19

a type I transmembrane protein found on all B cells and B-cell precursors and some follicular dendritic cells that acts as an accessory molecule for B-cell signal transduction; expressed in all B-cell neoplasms.
References in periodicals archive ?
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL [oral presentation].
Three of these ex vivo gene therapies are CAR T-cell cancer therapies that target CD19.
Flow cytometry showed a 96% variable size, clonal B cell population expressing CD10, CD11c, CD19, CD20, CD22, CD45, CD52, CD103, CD123, BCL2, and Kappa.
The NCI-sponsored trial is designed to enroll patients with CD22 positive cancers, with both CD19 positive and CD19 negative patients eligible for treatment.
Major finding: Patients receiving the biologic agent ofatumumab experienced suppression of multiple sclerosis lesions when their CD19 B-cell counts fell below 64 cells/mcL.
The cells were "reeducated" to recognize and destroy cancer cells that contain the protein CD19.
The CAR process starts when T cells are extracted from the blood of an individual and outfitted with two powerful features: a receptor on the outer cell surface that recognizes the protein CD19, present on most leukemic cells, and a powerful mechanism inside tile cell that triggers it to expand and proliferate once attached to the targeted protein.
The percentage of cells with CD20 expression correlated well with the percentage of cells showing CD19 expression in 11 of 12 cases (Figure 2).
CD19 is a receptor found on B cells and the majority of B cell malignancies but is not expressed on any other cell types, making it a favorable target for antibody-based therapy.
The primary antibodies used for immunocytochemistry were as follows: CD2 (clone AB75, NeoMarkers); CD3 (clone SP7, NeoMarkers); CD4 (clone 4B12, DAKO); CD5 (clone CD5/54/F6, DAKO); CD7 (clone 272, NeoMarkers); CD8 (clone C8/144B, DAKO); CD19 (clone LE-CD19, DAKO); CD20 (clone L26, NeoMarkers); CD30 (clone Ber-H2, DAKO); CD43 (clone DF-T1, NeoMarkers); CD45 (Clone 2B11 + PD7/26, DAKO); CD138 (clone M115, DAKO); ALK-1 (clone ALKO1, NeoMarkers); EMA (clone E29, DAKO); EBV/LMP (clone CS.
It increased the percentages of CD3 and CD19, but decreased the percentages of Mac-3 and CD11b markers, suggesting that differentiation of the precursor of T and B cells was promoted but macrophages were inhibited.